Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US-9492442-B2 · Nov 15, 2016 · US
Liposomes Useful for Drug Delivery
US2016339014A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016339014-A1 |
| Application number | US-201615227561-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 3, 2016 |
| Priority date | May 3, 2004 |
| Publication date | Nov 24, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
First claim
Opening claim text (preview).
What is claimed is: 1 . A pharmaceutical composition comprising irinotecan within a lipid matrix as irinotecan sucrose octasulfate, wherein the lipid matrix has a size of approximately 110 nm and comprises one or more phospholipids, and wherein the composition comprises a total of 500 mg of irinotecan base per mmol of total lipid matrix phospholipids. 2 . The composition of claim 1 , wherein the lipid matrix comprises a neutral phospholipid and cholesterol. 3 . The composition of claim 1 , wherein the lipid matrix comprises a lecithin and cholesterol. 4 . The composition of claim 1 , wherein the lipid matrix comprises a lecithin, a PEGylated lipid, and cholesterol. 5 . The composition of claim 1 , wherein the lipid matrix comprises DSPC, cholesterol, and PEG-DSPE in a molar ratio of 3:2:0.015. 6 . The composition of claim 1 , wherein the lipid matrix forms a vesicle encapsulating the irinotecan sucrose octasulfate. 7 . The composition of claim 6 , wherein the vesicle comprises DSPC, cholesterol, and PEG-DSPE in a molar ratio of 3:2:0.015. 8 . The composition of claim 1 , wherein the composition comprises a total of 500 mg of irinotecan base per mmol of total DSPC and PEG-DSPE. 9 . The composition of claim 8 , wherein the lipid matrix forms a vesicle encapsulating the irinotecan sucrose octasulfate. 10 . The composition of claim 9 , wherein the vesicle comprises DSPC, cholesterol, and PEG-DSPE in a molar ratio of 3:2:0.015. 11 . A pharmaceutical composition comprising irinotecan within a lipid matrix as irinotecan sucrose octasulfate, wherein the lipid matrix has a size of approximately 110 nm and comprises cholesterol and one or more phospholipids, and wherein the composition comprises a total of 500 mg of irinotecan base per mmol of total lipid matrix phospholipids, and wherein at least 90% of the irinotecan in the pharmaceutical composition is within the lipid matrix. 12 . The composition of claim 11 , wherein at least 90% of the irinotecan in the pharmaceutical composition is irinotecan sucrose octasulfate in the lipid matrix. 13 . The composition of claim 11 , wherein the lipid matrix forms a vesicle encapsulating the irinotecan sucrose octasulfate. 14 . The composition of claim 13 , wherein the vesicle comprises a lecithin, a PEGylated lipid, and cholesterol. 15 . The composition of claim 14 , wherein the vesicle comprises DSPC, cholesterol, and PEG-DSPE in a molar ratio of 3:2:0.015. 16 . The composition of claim 15 , wherein the lipid matrix comprises a total of 500 mg of irinotecan base per mmol of total DSPC and PEG-DSPE. 17 . The composition of claim 11 , wherein the composition comprises a total of 500 mg of irinotecan base per mmol of total DSPC and PEG-DSPE. 18 . A pharmaceutical composition comprising irinotecan within a lipid matrix as irinotecan sucrose octasulfate, wherein the lipid matrix has a size of approximately 110 nm and comprises DSPC, cholesterol, and PEG-DSPE, and wherein the composition comprises a total of 500 mg of irinotecan base per mmol of total DSPC and PEG-DSPE, and wherein at least 90% of the irinotecan in the pharmaceutical composition is in the irinotecan sucrose octasulfate within the lipid matrix. 19 . The composition of claim 18 , wherein the lipid matrix forms a vesicle encapsulating the irinotecan sucrose octasulfate. 20 . The composition of claim 19 , wherein the vesicle comprises DSPC, cholesterol, and PEG-DSPE in a molar ratio of 3:2:0.015.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antibacterial agents · CPC title
Antivirals · CPC title
Antineoplastic agents · CPC title
- A61K9/127Primary
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016339014A1 cover?
- The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
- Who is the assignee on this patent?
- Merrimack Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K9/127. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Nov 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).